Once-daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: Results of two multicentre, randomized and vehicle-controlled studies

British Journal of Dermatology

Volumn 166, Issue 3, 2012, Pages 633-641

  Fowler, J ^a   Jarratt, M ^b   Moore, A ^c   Meadows, K ^d   Pollack, A ^e   Steinhoff, M ^f   Liu, Y ^g   Leoni, M ^g  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b DermResearch Inc   (United States)

^c Arlington Center for Dermatology   (United States)

^d The Education and Research Foundation Inc   (United States)

^e Philadelphia Institute of Dermatology   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g Galderma RandD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRIMONIDINE;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; ERYTHEMA; FACE ERYTHEMA; FEMALE; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; ROSACEA; SIDE EFFECT; SKIN BURNING SENSATION; SKIN IRRITATION; TACHYPHYLAXIS; TELANGIECTASIA;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ADULT; AGED; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ERYTHEMA; FACIAL DERMATOSES; FEMALE; GELS; HUMANS; MALE; MIDDLE AGED; QUINOXALINES; ROSACEA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84863178633     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2011.10716.x     Document Type: Article

References (29)

1. Crawford GH, Pelle MT, James WD,. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol 2004; 51: 327-41. (Pubitemid 39178655)
2. Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: report of the National Rosacea Society expert committee on the classification and staging of rosacea. J Am Acad Dermatol 2002; 46: 584-7.
3. Berg M, Liden S,. An epidemiological study of rosacea. Acta Derm Venereol 1989; 69: 419-23. (Pubitemid 19226109)
4. Gupta AK, Chaudhry MM,. Rosacea and its management: an overview. J Eur Acad Dermatol Venereol 2005; 19: 273-85. (Pubitemid 40691703)
5. Wolf JE Jr, Del Rosso JQ,. The CLEAR trial: results of a large community-based study of metronidazole gel in rosacea. Cutis 2007; 79: 73-80.
6. Aksoy B, Altaykan-Hapa A, Egemen D, et al. The impact of rosacea on quality of life: effects of demographic and clinical characteristics and various treatment modalities. Br J Dermatol 2010; 163: 719-25.
7. Wilkin J, Dahl M, Detmar M, et al. Standard grading system for rosacea: report of the National Rosacea Society expert committee on the classification and staging of rosacea. J Am Acad Dermatol 2004; 50: 907-12. (Pubitemid 38685771)
8. Odom R, Dahl M, Dover J, et al. Standard management options for rosacea, Part I: overview and broad spectrum of care. Cutis 2009; 84: 43-7.
9. Odom R, Dahl M, Dover J, et al. Standard management options for rosacea, Part II: option according to subtype. Cutis 2009; 84: 97-104.
10. Singer MI,. Drug therapy of rosacea: a problem-directed approach. J Cutan Med Surg 1998; 2 (Suppl. 4): 20-3.
11. Powell FC,. Rosacea. N Engl J Med 2005; 352: 793-803.
12. Wilkin JK,. Rosacea: pathophysiology and treatment. Arch Dermatol 1994; 130: 359-62. (Pubitemid 24107876)
13. Marks R,. The enigma of rosacea. J Dermatol Treat 2007; 18: 326-8. (Pubitemid 350223201)
14. Steinhoff M, Buddenkotte J, Aubert J, et al. Clinical, cellular and molecular aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc 2011; 15: 2-11.
15. Schwab V, Sulk M, Seeliger S, et al. Neurovascular and neuroimmune aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc 2011; 15: 53-62.
16. Rahman MQ, Ramaesh K, Montgomery DNI,. Brimonidine for glaucoma. Expert Opin Drug Saf 2010; 9: 483-91.
17. Katz LJ,. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine study group. Am J Ophthalmol 1999; 127: 20-6. (Pubitemid 29036611)
18. Serle JB,. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The brimonidine study group III. Surv Ophthalmol 1996; 41 (Suppl. 1): S39-47. (Pubitemid 26422592)
19. Guarrera M, Brusati C, Rebora A,. Topical metronidazole does not abate UVB-induced erythema. Dermatology 2001; 203: 121-3. (Pubitemid 34701570)
20. Graf P,. Long-term use of oxy- and xylometazoline nasal sprays induces rebound swelling, tolerance, and nasal hyperreactivity. Rhiology 1996; 34: 9-13. (Pubitemid 26155374)
21. Adkins JC, Balfour JA,. Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension. Drugs Aging 1998; 12: 225-41. (Pubitemid 28130097)
22. Schuman JS, Horwitz BN, Choplin NT, et al. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Arch Ophthalmol 1997; 115: 847-52.
23. Pelle MT, Crawford GH, James WD,. Rosacea: II. Therapy. J Am Acad Dermatol 2004; 51: 499-512.
24. Lonne-Rahm SB, Fischer T, Berg M,. Stinging and rosacea. Acta Derm Venereol 1999; 79: 460-1.
25. 1-adrenergic receptor agonist, oxymetazoline. Arch Dermatol 2007; 143: 1369-71. (Pubitemid 350146279)
26. Wilkin JK,. Effect of nadolol on flushing reactions in rosacea. J Am Acad Dermatol 1989; 20: 202-5. (Pubitemid 19055625)
27. Craige H, Cohen JB,. Symptomatic treatment of idiopathic and rosacea-associated cutaneous flushing with propranolol. J Am Acad Dermatol 2005; 53: 881-4. (Pubitemid 41501387)
28. 2C- adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries. Am J Physiol Heart Circ Physiol 2000; 278: H1075-83. (Pubitemid 30235482)
29. 2- adrenergic constriction of isolated arterioles in diffuse scleroderma. Arthritis Rheum 2000; 43: 1886-90.